The safety and efficacy of UPTRAVI® were investigated in GRIPHON, a Phase 3 study assessing the long-term benefits of UPTRAVI® in pulmonary arterial hypertension (PAH) patients. The primary endpoint in GRIPHON was a composite of the time to the first morbidity or mortality event up to end of treatment.
UPTRAVI® demonstrated a 5-year survival estimate of over 75% in the open-label extension of the GRIPHON study.
Adapted from Galiè et al. 2018
*330 patients continuing on UPTRAVI® in the open-label extension after being randomised to UPTRAVI® in GRIPHON.
Advice on how to manage your UPTRAVI® patients, including details on dosage and side effects.
Details from the 2022 ESC/ERS guidelines to help you achieve and/or maintain a low-risk status for your patients with PAH.